Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK
- Conditions
- Graft Dysfunction
- Registration Number
- NCT02826811
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
BKV nephropathy (BKV) is one of the most frequent complications of kidney transplantation.
In the absence of specific anti-BKV treatment, pre-emptive reduction of immunosuppression is the main strategy that has proven effective in reducing the risk of BKVN. However, it exposes a transplant rejection risk estimated between 4 and 14% according to studies.
Despite the pre-emptive reduction of immunosuppression, a significant number of patients continue to progress towards BKVN suggesting that pre-emptive strategy is late. It's therefore urgent to develop new prognostic markers to identify earlier and more effectively patients with a higher risk of developing BKVN.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 170
Inclusion Criteria
- Patient over 18 years
- Grafted kidney patient between 1 July 2012 and 31 July 2014 at Strasbourg University Hospital with regular monitoring
Exclusion Criteria
- Patient under 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quantification of anti-BKV up to 12 months post-transplantation
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service de Virologie - Hôpital Civil
🇫🇷Strasbourg, France